According to reports, Baiyu Pharmaceuticals and Novartis have signed an exclusive licensing agreement for a small molecule anti-cancer drug. Under the agreement, Baiyu will receive an upfront payment of $70 million, as well as various milestone payments and corresponding royalties totaling up to $1.1 billion for development, registration, and commercialization. Novartis will obtain global exclusive rights for the innovative small molecule drug.
百裕制药与诺华签订在研抗肿瘤小分子药物独家许可协议
Baiyu Pharmaceuticals and Novartis have signed an exclusive licensing agreement for an investigational anti-cancer small molecule drug.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated